Recommended daily use of topical intranasal steroid spray continues to be underused for the treatment of chronic rhinosinusitis (CRS).
The study published in the JAMA Otolaryngology-Head & Neck Surgery evaluated the use of intranasal steroid spray for chronic rhinosinusitis in the canadian population.
‘Intranasal steroid spray is underused for the treatment of chronic rhinosinusitis in canadian population.’
Chronic rhinosinusitis is a condition were the cavities around the nasal passage gets inflammed and swollen. This results in breathing difficulty due to the building up of excess mucus in the nose. Use of topical intranasal steroid spray may be effective in treating the symptoms of chronic rhinosinusitis.
The study carried out by Luke Rudmik, M.D., M.Sc., and research team from the University of Calgary, Canada mainly focused on the utilization pattern of intranasal steroid therapy for chronic rhinosinusitis in canadian people by using a review of canadian population database in the year 2014 to 2015.
About 19,057 patients with chronic rhinosinusitis were evaluated for the use of intranasal steroid spray. The findings of the result reported that only 20 per 100 patients were found to use intranasal steroid spray with a quantity of 2.4 U (1 U = 1 bottle per month) per patient. This depicted a large geographic variation in the utilization of intranasal steroid spray.
Luke Rudmik writes that "Overall, the outcomes demonstrate that there is a significant under-use of INS spray for CRS patients; however, factors driving the underuse are currently unknown. Given that CRS practice guidelines provide strong recommendations for daily use of topical INS therapy, improving utilization of this treatment strategy may represent an opportunity to improve the quality of care".